Over the past few weeks biotech giant Amgen has been hit with delays for getting a potentially blockbuster drug to market; 15 states filed a federal lawsuit against the company; and a new study shows its anemia drug, Aranesp, may be causing more harm than good for some patients...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 26 biweekly issues
  • Subscriber-only digital content for prime stories
  • Book of Lists — the most comprehensive business resource in the Valley region
Yours for only $49